Loading…
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $84M | $27M | $22M | $17M | 23.8% | 14.4% | 16.9% |
| 2024 | $73M | $23M | $19M | $17M | 22.2% | 11.7% | 11.9% |
| 2023 | $66M | $21M | $17M | $5M | 24.1% | 23.0% | 34.0% |
| 2022 | $53M | $16M | $13M | $8M | 17.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 53.30 | 65.56 | 73.24 | 83.81 |
| Cost Of Revenue | 12.02 | 15.40 | 16.89 | 19.49 |
| Gross Profit | 41.28 | 50.16 | 56.35 | 64.32 |
| Operating Expense | 25.65 | 30.12 | 34.38 | 38.18 |
| Operating Income | 15.63 | 20.04 | 21.96 | 26.15 |
| EBITDA | 16.30 | 20.80 | 22.78 | 27.31 |
| EBIT | 15.63 | 20.04 | 21.96 | 26.15 |
| Pretax Income | 16.18 | 21.74 | 24.27 | 28.36 |
| Tax Provision | 3.35 | 4.55 | 5.04 | 5.88 |
| Net Income | 12.83 | 17.19 | 19.23 | 22.48 |
| Net Income Common Stockholders | 12.83 | 17.19 | 19.23 | 22.48 |
| Total Expenses | 37.68 | 45.53 | 51.28 | 57.67 |
| Interest Income | 0.58 | 1.86 | 2.19 | 2.01 |
| Research And Development | 2.28 | 2.86 | 2.83 | 2.98 |
| Selling General And Administration | 23.38 | 27.26 | 31.55 | 35.20 |
| Normalized EBITDA | 16.33 | 20.96 | 22.83 | 27.11 |
| Normalized Income | 12.85 | 17.32 | 19.27 | 22.32 |
| Basic EPS | 1.02 | 1.36 | 1.52 | 1.77 |
| Diluted EPS | 1.02 | 1.35 | 1.50 | 1.75 |
| Tax Effect Of Unusual Items | -0.01 | -0.03 | -0.01 | 0.04 |
| Tax Rate For Calcs | 0.21 | 0.21 | 0.21 | 0.21 |
| Total Unusual Items | -0.03 | -0.16 | -0.05 | 0.20 |
| Total Unusual Items Excluding Goodwill | -0.03 | -0.16 | -0.05 | 0.20 |
| Net Income From Continuing Operation Net Minority Interest | 12.83 | 17.19 | 19.23 | 22.48 |
| Reconciled Depreciation | 0.67 | 0.77 | 0.82 | 1.17 |
| Reconciled Cost Of Revenue | 12.02 | 15.40 | 16.89 | 19.49 |
| Net Interest Income | 0.58 | 1.86 | 2.19 | 2.01 |
| Net Income From Continuing And Discontinued Operation | 12.83 | 17.19 | 19.23 | 22.48 |
| Total Operating Income As Reported | 15.63 | 20.04 | 21.96 | 26.15 |
| Diluted Average Shares | 12.64 | 12.72 | 12.78 | 12.85 |
| Basic Average Shares | 12.56 | 12.60 | 12.67 | 12.72 |
| Diluted NI Availto Com Stockholders | 12.83 | 17.19 | 19.23 | 22.48 |
| Net Income Including Noncontrolling Interests | 12.83 | 17.19 | 19.23 | 22.48 |
| Net Income Continuous Operations | 12.83 | 17.19 | 19.23 | 22.48 |
| Other Income Expense | -0.03 | -0.16 | 0.12 | 0.20 |
| Other Non Operating Income Expenses | 0 | 0 | 0.16 | 0 |
| Special Income Charges | 0 | -0.01 | 0 | 0.20 |
| Gain On Sale Of Ppe | 0 | -0.01 | 0 | 0.20 |
| Gain On Sale Of Security | -0.03 | -0.15 | -0.04 | 0 |
| Net Non Operating Interest Income Expense | 0.58 | 1.86 | 2.19 | 2.01 |
| Interest Income Non Operating | 0.58 | 1.86 | 2.19 | 2.01 |
| Selling And Marketing Expense | 12.68 | 12.14 | 15.62 | 17.42 |
| General And Administrative Expense | 10.70 | 15.12 | 15.94 | 17.78 |
| Other Gand A | 10.70 | 15.12 | 15.94 | 17.78 |
| Operating Revenue | 53.30 | 65.56 | 73.24 | 83.81 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| IRADIMED CORPORATIONthis co. | IRMD | $1.1B | 47.83↓ discount | 11.31 | 23.8% | 37.30 |
| Zenas BioPharma, Inc. | ZBIO | $1.1B | - | - | -156.0% | -3.15 |
| EyePoint, Inc. | EYPT | $1.1B | - | 32.47 | -75.8% | -4.95 |
| Pacira BioSciences, Inc. | PCRX | $1.1B | 149.91 | 1.52 | 1.0% | 10.73 |
| CareDx, Inc. | CDNA | $1.1B | - |
| 3.49 |
| -7.0% |
| -124.58 |
| Teladoc Health, Inc. | TDOC | $1.1B | - | 0.77 | -14.5% | 39.94 |
| The Pennant Group, Inc. | PNTG | $1.1B | 36.56 | 3.22 | 7.9% | 25.85 |
| Septerna, Inc. | SEPN | $1.1B | - | 2.75 | -12.8% | -8.66 |
| Omeros Corporation | OMER | $1.0B | - | -8.61 | 2.8% | -9.24 |
| Peer Median | - | 93.23 | 2.75 | -9.9% | -4.05 | |